Xtl Biopharmaceuticals annual free cash flow
2015
2016
2019
2020
2024
Xtl Biopharmaceuticals Free Cash Flow (FCF) History (XTLB)
Xtl Biopharmaceuticals reported −$1.7M in free cash flow for fiscal 2024, a free cash flow margin of −370.73%.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$1.7M | — | — | −370.73% |
| 2020 | 2020-12-31 | −$851,000 | $59,000 | — | — |
| 2019 | 2019-12-31 | −$910,000 | — | — | — |
| 2016 | 2016-12-31 | −$1.7M | $129,000 | — | — |
| 2015 | 2015-12-31 | −$1.9M | — | — | — |
Xtl Biopharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$910,000 to −$1.7M, a net decrease of $762,000.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Xtl Biopharmaceuticals source filings ↗